


Thematic research area cancer mammae

The Oslo 2 study

Design

- Consecutive clinical study with research register and biobank material
- Patients undergoing breast cancer surgery at Oslo University Hospital, Vestre Viken Hospital Trust and Østfold Hospital
- 2400 breast cancer patients are included, among at 3500 patients
- Inclusion started in 2007, still recruiting patients



Biobank description

- ~13 aliquotes per patients, alltogether ~33.000 aliquotes, eBiobank system
- Fresh frozen tissue from primary tumor, EDTA blood, serum and plasma. From sub-cohorts: viable cells, circulating tumor cells/dissiminated tumor cells from bone marrow and blood, lymph nodes, tissue microrarray.
- In case of relapse of disease, tissue and blood samples are collected
- Tumor and blood samples analyzed at multiple levels for sub-cohorts:
 - Gene expression arrays (mRNA and miRNA)
 - SNP arrays/copy number changes
 - Metabolomic data (HR-MAS)
 - Protein (Reverse Phase Protein Arrays, Mass Spec, IHC)
 - Sequencing (RNAseq, WGS, Exome)
 - Mutation status of selected cancer genes



Clinical and Phenotypic data

- Patient characteristics:
 - Age at diagnosis: 57,2 years (24 – 92)
 - ER status: 76% ER+, 11% ER-
 - HER2 status: 11% HER2+, 81% HER2-
 - Tumor grade: 46% Grade 1, 22% Grade 2, 32% Grade 3
- Using Norwegian Breast Cancer Registry as clinical database, allows for high quality data and easy updates
- Resources utilised
 - Norwegian Breast Cancer Registry
 - Cause of Death Registry
 - EMR data
- Patients can be re-contacted, patients are followed up after standard clinical controls


Research focus

- Research group is focusing on clinical and translational breast cancer research for better diagnoses and treatment
- Areas of special interest to collaborate with industry: biomarker discovery, prediction of prognosis, sub-classification of breast cancer patients, testing of laboratory instruments, development of methodology
- Research group special competence: clinical-, translational-, and statistical breast cancer research
- Collaborators:



- Ongoing industry collaborations: Nanostring Technologies

Regional network for breast cancer research



For Better Diagnosis and Treatment

Series	No	Mouse models	Healthy breast	Benign	DCIS	Small invasive	Invasive	Adv. stage
MDG-N	120		■					
MDG-T	66				■		■	
MicMa	123				■		■	
Oslo2	2400				■		■	
AHUS	131		■				■	■
MAM04	450				■		■	
NeoAva	150				■		■	
OsloVal	184				■		■	■
Oslo1	903				■		■	
NeoTax	236						■	
HER2	40						■	■
SATT	1121					■	■	
I-BCT	80						■	■
MetAction	11						■	■
Xenografts	7	■						
SUS-1	399					■	■	■
SUS-2	2741					■	■	■

How to collaborate?

- Access to data and material are considered in the steering group (www.osbreac.no) after enquiry, new collaborations and sub-projects are reported to REC and the institution by the PI before extradition
- For more information about research activities and clinical studies: www.breastcancerresearch.no
- Contact information: Kristine.Sahlberg@vestreviken.no / + 47 98 64 12 29

